ID: ALA310458

Max Phase: Preclinical

Molecular Formula: C12H15N3O

Molecular Weight: 217.27

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Oc1[nH]cnc2c(CC3CCCC3)cnc1-2

Standard InChI:  InChI=1S/C12H15N3O/c16-12-11-10(14-7-15-12)9(6-13-11)5-8-3-1-2-4-8/h6-8,16H,1-5H2,(H,14,15)

Standard InChI Key:  DSCXEPCBJOUADF-UHFFFAOYSA-N

Associated Targets(non-human)

Purine-nucleoside phosphorylase 70 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 217.27Molecular Weight (Monoisotopic): 217.1215AlogP: 2.35#Rotatable Bonds: 2
Polar Surface Area: 61.80Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.30CX Basic pKa: 0.82CX LogP: 2.30CX LogD: 2.25
Aromatic Rings: 0Heavy Atoms: 16QED Weighted: 0.81Np Likeness Score: -0.02

References

1. Niwas S, Chand P, Pathak VP, Montgomery JA..  (1994)  Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.,  37  (15): [PMID:8057293] [10.1021/jm00041a027]

Source